Abstract
Background The leading cause of mortality for patients with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome is development of Malignant Peripheral Nerve Sheath Tumor (MPNST), an aggressive soft tissue sarcoma. In the setting of NF1, this cancer type frequently arises from within its common and benign precursor, plexiform neurofibroma (PN). Transformation from PN to MPNST is challenging to diagnose due to difficulties in distinguishing cross-sectional imaging results and intralesional heterogeneity resulting in biopsy sampling errors.
Methods and Findings This multi-institutional study from the National Cancer Institute and Washington University in St. Louis used fragment size analysis and ultra-low-pass whole genome sequencing (ULP-WGS) of plasma cell-free DNA (cfDNA) to distinguish between MPNST and PN in patients with NF1. Following in-silico enrichment for short cfDNA fragments and copy number analysis to estimate the fraction of plasma cfDNA originating from tumor (tumor fraction), we developed a noninvasive classifier which differentiates MPNST from PN with 86% pre-treatment accuracy (91% specificity, 75% sensitivity), and 89% accuracy on serial analysis (91% specificity, 83% sensitivity). Healthy controls without NF1 (subjects = 16, plasma samples = 16), PN (subjects = 23, plasma samples = 23), and MPNST (subjects = 14, plasma samples = 46) cohorts showed significant differences in tumor fraction in plasma (P = 0.001 as well as cfDNA fragment length (P < 0.001) with MPNST samples harboring shorter fragments and being enriched for tumor-derived cfDNA relative to PN and healthy controls. Mutational analysis demonstrated focal NF1 copy number loss in PN and MPNST patient plasma but not in healthy controls. Greater genomic instability including alterations associated with malignant transformation (focal copy number gains in chromosome arms 1q, 7p, 8q, 9q, and 17q; focal copy number losses in SUZ12, SMARCA2, CDKN2A/B, and chromosome arms 6p and 9p) was more prominently observed in MPNST plasma. Furthermore, the sum of longest tumor diameters (SLD) visualized by cross-sectional imaging correlated significantly with paired tumor fractions in plasma from MPNST patients (r = 0.39, P = 0.024). On serial analysis, tumor fraction levels in plasma dynamically correlated with treatment response to therapy and minimal residual disease (MRD) detection before relapse. Study limitations include a modest MPNST sample size despite accrual from two major referral centers for this rare malignancy, and lack of uniform treatment and imaging protocols representing a real-world cohort.
Conclusions Tumor fraction levels derived from cfDNA fragment size and copy number alteration analysis of plasma cfDNA using ULP-WGS significantly correlated with MPNST tumor burden, accurately distinguished MPNST from its benign PN precursor, and dynamically correlated with treatment response. In the future, our findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations.
Why was this study done?
➢ Neurofibromatosis 1 (NF1) is the most common inherited cancer predisposition syndrome.
➢ The leading cause of mortality in NF1 is malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma that arises from a benign plexiform neurofibroma (PN) precursor lesion.
➢ Transformation from PN to MPNST is challenging to detect by imaging (due to difficulty in distinguishing PN from MPNST radiologically) or by biopsy (due to intralesional heterogeneity), which often delays the diagnosis of MPNST and results in a worsened prognosis.
What did the researchers do and find?
➢ We conducted a multi-institutional study involving two large NF1 referral centers, the National Cancer Institute and Washington University in St. Louis, involving 73 patients from whom plasma cell-free DNA (cfDNA) was analyzed using ultra-low-pass whole genome sequencing (ULP-WGS).
We found that cfDNA from patients with MPNST harbors a shorter fragmentation profile compared to patients with PN or healthy donors. Using sequencing reads from this fragmentation profile, we quantified genome-wide copy number alterations (CNAs) in cfDNA and used CNAs to estimate the fraction of plasma cfDNA originating from tumor.
➢ Tumor fraction in plasma cfDNA distinguished pre-treatment MPSNT from PN with 86% accuracy. Plasma cfDNA from MPNST and PN patients harbored focal copy number loss of NF1, not found in healthy donors. Strikingly, MPNST patient cfDNA also had significantly greater tumor genomic instability compared to PN, with copy number alterations in key genomic loci previously observed in MPNST tissue (i.e., gain of chromosome arm 8q and loss of 9p), which enabled sensitive and specific liquid biopsy discrimination of MPNST from PN.
➢ Plasma-derived tumor fraction correlated with tumor size from imaging in MPNST patients, and serial cfDNA analysis demonstrated the potential for noninvasive detection of minimal residual disease, treatment response assessment, and the potential for even greater assay sensitivity.
What do these findings mean?
➢ Our findings suggest that cfDNA fragment analysis followed by ULP-WGS has the potential to be developed as a biomarker for treatment response, and as a screening assay for early detection of MPNST.
➢ This study provides, to our knowledge, the first evidence for the ability of liquid biopsy to distinguish between benign and malignant tumors in a heritable cancer predisposition syndrome.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: A.A.C. has patent filings related to cancer biomarkers. A.A.C. has served as a consultant/advisor to Roche, Tempus, Geneoscopy, NuProbe, Fenix Group International and Guidepoint, and receives research support from Roche. A.A.C. is an inventor of intellectual property licensed to Biocognitive Labs, has stock options in Geneoscopy, and ownership interests in Droplet Biosciences. F.Q. has stocks: Centene. No potential conflicts of interest were disclosed by the other authors.
Funding Statement
This work was supported by grants from the Childrens Cancer Foundation NextGen Award (R.T.S.), the National Institute of General Medical Sciences (5T32GM007067 supporting P.A.J.), the NCI Center for Cancer Research Intramural Research Program (1ZIABC011722-04 supporting R.T.S, J.F.S., and 1ZIABC010801-13 supporting B.C.W.), the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research (A.C.H.), the St. Louis Mens Group Against Cancer (A.C.H.), the Washington University Alvin J. Siteman Cancer Research Fund (A.A.C.), the National Cancer Institute (1K08CA238711-01 to A.A.C.), the Cancer Research Young Investigator Award (A.A.C.), and the V Foundation for Cancer Research (A.A.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NCI protocol NCT01109394, NIH Intramural IRB identifier 10C0086; NCI protocol NCT00924196, NIH Intramural IRB identifier 08C0079; WUSTL protocol NCT04354064, Washington University in St. Louis School of Medicine Human Research Protection Office IRB identifiers 201903142 and 201203042
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The manuscript has been updated to reflect a technical improvement in the method. The 2017 Nature Communications paper first describing ichorCNA (Adalsteinsson et al., 2017) reported that at least 10% tumor content can be quantified from cfDNA sequenced with 0.1x coverage. To achieve a lower limit of detection in the setting of cancer vs. pre-cancer detection, we sequenced our libraries more deeply to ~0.2-6x coverage, although we did not previously do a formal analysis correlating sequencing coverage with assay performance. We have now done this analysis, comparing ~0.3x coverage (5 million read-pairs) to ~0.6x coverage (10 million read-pairs) plasma WGS, which reveals improved assay performance with higher sequencing depth, as shown in new Supplemental Figure 4 in the updated manuscript. We were able to apply ~0.6x coverage NGS to our original full MPNST cohort (n=14 subjects, n=46 samples), healthy donors (n=16 subjects, n=16 samples), and an adequately powered subset of the PN cohort (n=23 subjects, n=23 samples) per our pre-study sample size calculation (see Methods). The ability of deeper sequencing to optimize tumor fraction inference following low-pass WGS of plasma cfDNA for cancer vs. pre-cancer detection is a new technical innovation which we now highlight in our updated Discussion section.
Data Availability
Data will be publicly available following print publication of the study.
Abbreviations
- AN
- atypical neurofibroma
- CNA
- copy number alteration
- cfDNA
- cell-free DNA
- ctDNA
- circulating tumor DNA
- FFPE
- formalin-fixed paraffin-embedding
- IQR
- interquartile range
- NCI
- National Cancer Institute
- NF1
- neurofibromatosis type 1
- PBMC
- peripheral blood mononuclear cell
- PN
- plexiform neurofibroma
- MPNST
- malignant peripheral nerve sheath tumor
- MRD
- minimal residual disease
- ROC
- receiver operating characteristic
- SLD
- sum of longest diameters
- ULP-WGS
- ultra-low-pass whole genome sequencing
- WES
- whole exome sequencing
- WGS
- whole genome sequencing
- WUSTL
- Washington University in Saint Louis
